Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis

NCT04535349

Status	RECRUITING
Phase	Not Applicable
Sponsor	University Hospital, Caen
Enrollment	35 participants

Key Eligibility Criteria

Inclusion (5)

- Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures that required/requires treatment with a diuretic for improvement, and an increase of BNP \>200 pg/mL and/or NT-proBNP \>500 pg/mL
- Suspected cardiac ATTR amyloidosis
- Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness \> 12 mm
- Patient signed consent
- Contraception method

Exclusion (7)

- New York Heart Association (NYHA) functional class IV despite diuretic treatment
- Life expectancy \<6 month due to the severity of cardiac amyloidosis and/or comorbidities
- Aortic valve surgical or percutaneous replacement within 30 days or planned within months
- Presence of primary (light chain) amyloidosis
- Contraindication to tafamidis

... and 2 more (see full listing online)

Locations (2 total)

CHU de Caen, Caen, France
Clinique du Bois, Lille, France

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.